Hoffmann Christian
Infektionsmedizinisches Centrum Hamburg, Grindelallee 35, 20146 Hamburg, Germany.
Eur J Med Res. 2007 Oct 15;12(9):385-90.
According to their cellular coreceptor tropism, HIV variants are termed R5 if they use CCR5 as a coreceptor, whereas viruses with a preference for CXCR4 are termed X4. The prevalence of R5, X4 and dual/mixed (D/M) strains shows considerable variation in different patient populations. In treatment naive patients, R5 strains are found in 80-90%, compared to only 50-55% in patients with antiretroviral exposure. The most important predictor of R5 tropism seems to be a higher CD4 T-cell count in both naive and antiretrovirally pretreated patients. A low HIV plasma viremia seems to be associated with R5 tropism only in untreated patients. As the benefit of the new antiretroviral drug class of the CCR5 coreceptor antagonists will be probably limited to the HIV-infected patients harbouring R5 strains, determination of viral coreceptor tropism has become an important diagnostic prerequisite for the treatment of HIV infection. This review will focus on current knowledge of the epidemiology of HIV coreceptor tropism.
根据其细胞共受体嗜性,HIV变体若使用CCR5作为共受体,则被称为R5型,而偏好CXCR4的病毒则被称为X4型。R5、X4和双/混合(D/M)毒株的流行率在不同患者群体中存在显著差异。在未经治疗的患者中,80%-90%可检测到R5毒株,而在接受抗逆转录病毒治疗的患者中,这一比例仅为50%-55%。R5嗜性的最重要预测因素似乎是初治患者和接受过抗逆转录病毒治疗患者中较高的CD4 T细胞计数。低HIV血浆病毒血症似乎仅在未治疗患者中与R5嗜性相关。由于新型抗逆转录病毒药物CCR5共受体拮抗剂的益处可能仅限于携带R5毒株的HIV感染患者,因此确定病毒共受体嗜性已成为治疗HIV感染的重要诊断前提条件。本综述将聚焦于HIV共受体嗜性流行病学的当前知识。